NDA 221154 · Aicuris Anti-Infect
Hovilpri
Pritelivir Mesylate · Oral
NovelPriority reviewCDER novel approval, Oct 9, 2026: To treat adults with weakened immune systems who have mucocutaneous lesions caused by herpes simplex virus infection and have not responded to other therapies
Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Oct 9, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
6
1 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. FDA's summary: To treat adults with weakened immune systems who have mucocutaneous lesions caused by herpes simplex virus infection and have not responded to other therapies
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- HOVILPRI · PRITELIVIR MESYLATE EQ 100MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Pritelivir" as an intervention, any sponsor and status, largest first.
- Trial on Efficacy and Safety of Pritelivir Ointment for Treatment of Labial HerpesPivotal-lookingCompleted
AiCuris Anti-infective Cures AGIndustry
NCT02871492 · 362 participants · Start Nov 29, 2016 · Primary completion Sep 29, 2017
Drug: Pritelivir 5% w/w ointment; Pritelivir ointment matching placebo and 1 more · For: Herpes Labialis
Sites: Scottsdale, Arizona; Santa Rosa, California; Pinellas Park, Florida · 10 sites in all
- Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised SubjectsPivotal-lookingCompleted
AiCuris Anti-infective Cures AGIndustry
NCT03073967 · 158 participants · Start May 8, 2017 · Primary completion Aug 15, 2025
Drug: Pritelivir; Investigator's choice · For: HSV Infection
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 70 sites in all
- Safety and Efficacy Study for a New Antiviral Drug to Treat Genital Herpes Type 2Pivotal-lookingCompleted
AiCuris Anti-infective Cures AGIndustry
NCT01047540 · 156 participants · Start Mar 2010 · Primary completion Dec 2010
Drug: AIC316; AIC316 and 3 more · For: HSV-2
Sites: Miami, Florida; Indianapolis, Indiana; Portland, Oregon · 6 sites in all
AiCuris Anti-infective Cures AGIndustry
NCT01658826 · 91 participants · Start Oct 2012 · Primary completion May 2013
Drug: AIC316; Valacyclovir · For: Genital Herpes
Sites: Indianapolis, Indiana; Portland, Oregon; Houston, Texas · 4 sites in all
AiCuris Anti-infective Cures AGIndustry
NCT05671029 · 64 participants · Start Dec 4, 2022 · Primary completion May 18, 2023
Drug: Pritelivir and moxifloxacin placebo; Pritelivir placebo, moxifloxacin and moxifloxacin placebo and 1 more · For: Healthy Subjects
Sites: London, United Kingdom
AiCuris Anti-infective Cures AGIndustry
NCT05513625 · 16 participants · Start Jul 13, 2020 · Primary completion Oct 13, 2020
Drug: Pritelivir; ESO and pritelivir · For: HSV Infection
Sites: Cincinnati, Ohio
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and Safety of Pritelivir vs Foscarnet for the Treatment of Acyclovir-Refractory Herpes Simplex Virus Infection in Immunocompromised Adults: A Randomized, Open-Label Phase 2 Trial.
Kotton CN, Workowski KA, Kumar PN, et al. · Open Forum Infect Dis 2026 · Clinical Trial
- First-in-Human, Single- and Multiple-Ascending-Dose, Food-Effect, and Absolute Bioavailability Trials to Assess the Pharmacokinetics, Safety, and Tolerability of Pritelivir, a Nonnucleoside Helicase-Primase Inhibitor Against Herpes Simplex Virus in Healthy Subjects.
Kropeit D, Bonsmann S, von Richter O, et al. · Clin Pharmacol Drug Dev 2023 · Clinical Trial, Research Support, Non-U.S. Gov't
- No Evidence of Pritelivir Resistance Among Herpes Simplex Virus Type 2 Isolates After 4 Weeks of Daily Therapy.
Edlefsen PT, Birkmann A, Huang ML, et al. · J Infect Dis 2016 · Randomized Controlled Trial
- Helicase-primase inhibitor pritelivir for HSV-2 infection.
Wald A, Corey L, Timmler B, et al. · N Engl J Med 2014 · Multicenter Study, Randomized Controlled Trial
- Effect of Pritelivir Compared With Valacyclovir on Genital HSV-2 Shedding in Patients With Frequent Recurrences: A Randomized Clinical Trial.
Wald A, Timmler B, Magaret A, et al. · JAMA 2016 · Clinical Trial, Phase II, Multicenter Study
- Evaluation of the Clinical Drug-Drug Interaction Potential of Pritelivir on Transporters and CYP450 Enzymes Using a Cocktail Approach.
de Vries M, Bonsmann S, Pausch J, et al. · Clin Pharmacol Drug Dev 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Aicuris Anti-Infect
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.